US 11,702,394 B2
Inhibitors of phospholipid synthesis and methods of use
Arvin Gouw, San Francisco, CA (US); Dean W. Felsher, San Mateo, CA (US); Feng Jin, Stanford, CA (US); Richard N. Zare, Stanford, CA (US); Katherine Margulis, San Francisco, CA (US); Steven R. Schow, Redwood City, CA (US); Robert J. Greenhouse, Newark, CA (US); David Loughhead, Belmont, CA (US); and Steven Richards, Stanford, CA (US)
Assigned to The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
Appl. No. 16/968,836
Filed by The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
PCT Filed Feb. 22, 2019, PCT No. PCT/US2019/019185
§ 371(c)(1), (2) Date Aug. 10, 2020,
PCT Pub. No. WO2019/165232, PCT Pub. Date Aug. 29, 2019.
Claims priority of provisional application 62/634,526, filed on Feb. 23, 2018.
Prior Publication US 2021/0002240 A1, Jan. 7, 2021
Int. Cl. A61P 35/00 (2006.01); C07D 295/092 (2006.01); C07C 311/08 (2006.01)
CPC C07D 295/092 (2013.01) [A61P 35/00 (2018.01); C07C 311/08 (2013.01)] 16 Claims
 
1. A GPAT inhibitor of one of formulae (IA), (IB), (IC):

OG Complex Work Unit Chemistry
wherein:
R1 is selected from deuterated alkyl and substituted deuterated alkyl;
R2, and R3 are each independently selected from alkyl, substituted alkyl, deuterated alkyl and substituted deuterated alkyl;
or a pharmaceutically acceptable salt or solvate thereof.